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Purpose: To evaluate haptoglobin (Hp) in ovarian cyst fluid as a diagnostic biomarker for 
epithelial ovarian cancers (EOCs) using surface-enhanced Raman spectroscopy (SERS)-based 
in vitro diagnostic assay for use in an intraoperative setting.
Methods: SERS-based method was used to detect and quantify Hp in archived ovarian cyst 
fluids collected from suspicious ovarian cysts and differentiate benign tumors from EOCs. The 
diagnostic performance of SERS-based assay was verified against the histopathology conclu-
sions and compared with the results of CA125 test and frozen sections.
Results: Hp concentration present in the clinical cyst fluid measured by SERS was normalized 
to 3.3 mg/mL of standard Hp. Normalized mean values for patients with benign cysts were 0.65 
(n=57) and malignant cysts were 1.85 (n=54), demonstrating a significantly (P<0.01) higher Hp 
in malignant samples. Verified against histology, Hp measurements using SERS had a sensitivity 
of 94% and specificity of 91%. Receiver operating characteristic curve analysis of SERS-based 
Hp measurements resulted in area under the curve of 0.966±0.03, establishing the robustness of 
the method. CA125 test on the same set of patients had a sensitivity of 85% and specificity of 
90%, while frozen section analysis on 65 samples had 100% sensitivity and specificity.
Conclusion: With a total execution time of <10 minutes and consistent performance across 
different stages of cancer, the SERS-based Hp detection assay can serve as a promising intra-
operative EOC diagnostic test.
Keywords: surface-enhanced Raman spectroscopy, haptoglobin, epithelial ovarian cancer, 
ovarian cyst fluid, point-of-care diagnostics
Introduction
Ovarian cancer is the most lethal gynecological cancer and the eighth most common 
cause of death in women.1 Ninety percent of the ovarian cancers arise from the thin layer 
of epithelial tissue that covers the ovaries and hence called epithelial ovarian cancer 
(EOC). The 5-year prognosis for EOC is dismal as the disease often presents itself in 
the advanced stages with metastasis to the peritoneal and pelvic cavities.2,3 At the late 
stage, the 5-year prognosis is <40%,4 whereas if diagnosis was made at an early stage, 
the 5-year prognosis is >90%.5 Women with EOCs are either asymptomatic or would 
have “vague” symptoms at an early stage, which poses a challenge to physicians and 
often leads to significant delays in diagnosis.6,7 Currently, there is no known screening 
modality which is cost-effective and helps in lowering mortality rates.4,8
The use of intraoperative frozen section (FS) has been proposed to prevent delay in 
primary surgery. Although intraoperative FS has been widely used in clinical settings,9–11 
it does suffer from several limitations such as variation in accuracy as a result of large 
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cyst size, nonuniformity of the tissue malignancy resulting 
in sampling error, and finally, limited availability of staining 
methods11,12 resulting in misdiagnosis or underdiagnosis of 
the disease condition. Hence, there is a strong need for an 
intraoperative diagnostic solution.
Haptoglobin (Hp), an acute phase serum glycoprotein, is 
observed to be elevated in the sera and ascetic fluid of EOC 
patients,13,14 and thus, it serves as an effective biomarker for 
EOC. However, due to the time-consuming biochemical 
methods to detect Hp, its intraoperative use as a biomarker is 
impractical. The widely available method so far for detecting 
Hp is the use of ultraviolet spectroscopy similar to the standard 
ELISA assay.13,14 This technique is affected by poor sensitivity 
at lower concentrations of the peroxidase product and also any 
coloration arising from the cyst fluid samples (which can range 
from transparent to dark brown). Therefore, a highly sensitive 
method that can detect low concentrations of Hp and remains 
unaffected by the sample coloration would make a promising 
intraoperative diagnostic test.
We have previously demonstrated the proof of concept 
for the detection and quantification of Hp using a surface-
enhanced Raman spectroscopy (SERS)-based assay with 
a detection limit of 50 nM and which is not affected by 
exogenous coloration due to the unique fingerprint spectrum 
associated with the molecule of interest.15 In the current study, 
we hypothesize that our highly sensitive and efficient SERS-
based Hp detection assay can serve as an in vitro diagnostic 
test in an intraoperative setting to rapidly differentiate benign 
tumors from malignant EOCs based on the amount of Hp in 
the ovarian cyst fluid (OCF).
Materials and methods
Chemicals such as 3,3′,5,5′-tetramethylbenzidine (TMB), 
 citric acid, buffer solutions along with biologicals such as 
hemoglobin (Hb) and BSA were purchased from Sigma-
Aldrich (St Louis, MO, USA). Hp antigen of human ori-
gin was purchased from Abcam (Cambridge, MA, USA). 
Au  colloid (60 nm) was obtained from BBI solutions 
(Crumlin, UK).
Clinical sample collection
OCF samples were collected during surgery without spillage 
into the abdominal cavity. Samples were later transported on 
ice to the laboratory, centrifuged at 2,000×g for 10 minutes at 
4°C, and the supernatant archived at –80°C until analysis. All 
specimens were collected after obtaining written informed 
consent from each subject (parent or legal guardian provided 
the written informed consent for any patient under the age of 
18) and used in accordance with the local ethics committee 
approved protocol numbered D2007/240.
sample preparation
Hp forms an irreversible complex with Hb in a ratio of 
1:0.5–0.9, as detailed in the Sigma-Aldrich website. Purified 
Hp (ab90924) or clinical OCFs were mixed with 3.3 mg/mL 
human Hb in equal volumes and left to react for several min-
utes to form (Hb–Hp) complex. Five microliters of (Hb–Hp) 
complex is added to 10 µL of TMB in an Eppendorf tube and 
allowed to react for a few minutes at room temperature. Stop 
solution was added and vortexed well to quench the reaction. 
Gold nanoparticles (5.2×1.010 particles/mL) were added to 
the reaction mixture. Twenty microliters of the above reaction 
mixture was dropped onto a clean glass slide with a cover 
slip on top to be read using Raman microscope. Figure 1 
shows the schematic of SERS-based assay for Hp detection.
Measurement of Hp using SERS
SERS measurements were performed on all 111 OCFs using 
Raman microscope (InVia; Renishaw) with a 633 nm excita-
tion laser, 1,800 line/mm grating, and a cooled charge-coupled 
device (–70°C). A 20× objective lens (NA 0.4) was used to 
deliver the laser beam and collect scattered light. The laser 
spot size was around 3 µm with a power of 0.28 mW. Multiple 
measurements with an integration time of 10 seconds were 
taken at different locations across the sample region and 
data were averaged. Spectra were background subtracted by 
a 6-order polynomial fit before the curve-fitting procedure 
using WiRE 3.4 Software (Renishaw plc., Wotton-under-Edge, 
UK). The instrument was calibrated using a silicon standard at 
520 cm−1. Raman data postprocessing and analysis were per-
formed in Matlab (Mathworks, Natick, MA, USA). All SERS 
measurements were normalized against 3.3 mg/mL of Hp.
statistical analysis and graphs
Binary classification
We evaluated the diagnostic performance of the SERS assay 
using four classifiers, including linear discriminant analy-
sis, logistic regression (LR), support vector machine, and 
K-nearest neighbor classifier (with K set at 3). A repeated 
cross-validation technique was used to better generalize 
the diagnostic performance of the assay with these four 
classifiers. Holdout procedure, a form of cross-validation, 
is implemented to randomly partition the given data set, so 
that 80% of the total data set is used for training the model 
and the remaining 20% for testing each classifier. Such 
cross-validation process was then repeated 1,000 times, 





yielding 1,000 random partitions of the original data set from 
which performance measures were computed and averaged. 
The performance measures included accuracy, sensitivity, 
specificity, precision, and F1-score. In addition, following 
the same cross-validation procedure, LR was applied to 
construct receiver operating characteristic (ROC) curves, 
in which were plotted sensitivity against false-positive rate 
(1−specificity). The mean and SD of area under the curve 
(AUC) were computed from these ROCs.
statistical analysis
Diagnostic performances of the SERS assay, CA125 test, and 
FS analysis on clinical samples were evaluated using clinical 
research calculators in VassarStats: Statistical Computation 
Web Site.
graphs
Graphs were plotted using Origin 9.1 (OriginLab, Northamp-
ton, MA,USA).
Results
Clinical characteristics of patients
We performed a retrospective analysis on archived OCF from 
patients who were consecutively recruited, aged 16–82 years 
between December 2003 and January 2016, and undergoing 
either laparoscopy or laparotomy for cystic epithelial ovarian 
tumors at the National University Hospital, Singapore. All 
tumors were defined by histopathologic diagnoses and staged 
according to the International Federation of Gynecology and 
Obstetrics staging for ovarian cancer.16 The histopathology 
diagnoses (FS, when conducted, and paraffin) for the 111 
samples were known prior to analysis. Ovarian dermoid 
cysts, endometriotic cysts, pelvic inflammatory disease, 
tubo-ovarian abscesses, borderline tumors, and solid and 
frank malignant tumors were excluded from this study. OCF 
samples were collected either at laparoscopy or laparotomy 
without spillage into the abdominal cavity. In total, there 
were 111 samples including 57 benign and 54 malignant 
samples. There were 29 malignancies in stage 1, 3 in stage 
2, 15 in stage 3, and 7 in stage 4. The clinical characteristics 
of patients from whom OCF was collected are summarized 
in Table 1.
SERS-based detection and quantification 
of hp
All OCF samples were blinded for malignancy and tumor 
stage and subjected to SERS-based Hp detection and quan-
tification as described previously.15 Briefly, we exploited the 
peroxidase activity of (Hb–Hp) complex in converting the 
SERS-inactive TMB substrate to SERS-active TMB2+ (Figure 
S1). SERS spectra of TMB2+ exhibited unique peaks at 1,191, 
1,337, and 1,605 cm−1 wavenumbers (Figure S2), of which 
Figure 1 schematic of seRs-based assay for hp detection.
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1,605 cm−1 was very prominent and changed linearly with 
increasing concentrations of Hp (Figure S3). Processed and 
normalized SERS spectral data for Hp quantification resulted 
in a mean of 0.65 for 57 OCFs collected from benign tumors 
and a mean of 1.85 for 54 OCFs collected from malignant 
tumors. Normalized Hp levels were significantly (P<0.01) 
higher in malignant OCFs than benign OCFs, suggesting the 
elevated levels of Hp in OCFs from patients with malignant 
tumors. A two-dimensional Kernel plot of the normalized 
data (Figure 2A, B) demonstrated the clear demarcation in 
Hp levels between benign and malignant OCFs. ROC curve 
analysis of SERS-based detection of Hp (Figure 2C) resulted 
in mean and SD of 0.966±0.03 for the AUC. To compare the 
SERS results with those of CA125 serum, we also performed 
the ROC curve analysis for CA125 serum from blood (Figure 
S4) and found the AUC to be 0.940±0.023, thus demonstrat-
ing the robustness of SERS-based Hp detection method 
with respect to CA125 serum, although it was not clinically 
significant.
Diagnostic performance of seRs-based 
hp detection
The diagnostic performance of SERS-based Hp detection 
assay on all 111 OCFs was verified against histology (Table 
2) using VassarStats: Statistical Computation Web Site. The 
assay can differentiate between benign and malignant tumors 
with 94% sensitivity and 91% specificity. The assay can cor-
rectly identify 91% (positive predictive value, n=52/57) of 
benign samples and 94.5% of malignant samples (negative 
predictive value [NPV], n=51/54). The higher NPV of 94.5% 
for SERS-based assay implies false-negative predictions in 
5.5% of the samples. SERS-based Hp detection also main-
tained a high sensitivity regardless of the stages of cancer, 
with 97% for stage 1, 100% for stage 2, 93% for stage 3, 
and six out of seven seven samples for stage 4 (Table 3). In 
particular, among women diagnosed with early-stage EOC, 
six had high-grade serous carcinoma subtype. In all the high-
grade serous carcinoma samples, normalized Hp ratio (range 
1.09–4.43) was higher than the cut-off ratio of 1 (Table 4), 
suggesting the usefulness of SERS assay in picking up early-
stage high-grade lesions efficiently.
Diagnostic performance of seRs 
compared to Ca125
As CA125 test with a cut-off of 35 U/mL17 is widely used 
as the benchmark in clinics to assess the risk of malig-
nancy in ovarian cancer, we compared the performances of 
SERS-based Hp detection assay to CA125 test on the all 
111 patients (Tables 5 and 6) using VassarStats: Statistical 
Computation Web Site. Prediction of malignancy based on 
CA125 test had a sensitivity of 85% and specificity of 90%. 
The assay can correctly identify 88% of benign samples 
(n=51/57) and 87% of malignant samples (n=46/54). Lower 
NPV of 87% for CA125 test implied >10% false-negative 
values, thus suggesting that Hp had superior diagnostic 
accuracy than CA125.
Diagnostic performance of seRs 
compared to Fs
FS histology was available for 65 of the 111 cases studied 
(58.6%; 28 benign and 37 malignant cases). For the 65 cases 
with FS performed, we compared the diagnostic accuracy of 
SERS assay and FS results against the gold standard paraffin 
histopathology results. The overall accuracy in determination 
Table 1 Summary of clinical characteristics of patients from whom ovarian cyst fluid samples were collected
Characteristics All samples (N=111) Benign (n=57) Malignant (n=54) P-value
age (years), mean ± seM 48.0±1.3 43.64±2.0 52.9±1.4 P=0.0002*
histological type, n (%)















Mixed epithelial 8 (7.2)
Cancer stage, n (%)







Note: *Mann Whitney test of significance.
Abbreviation: na, not applicable.





of the status of malignancy was 90.8% for cyst fluid Hp by 
SERS and 100.0% for FS (Table 7). In two cases (3.1%) of 
OCF Hp measurements by SERS, there was underdiagnosis 
of malignant tumors and in four cases (6.2%), there was 
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Figure 2 Kernel density representation of the clinical sample from the benign and malignant categories.
Notes: (A) Normalized Hp level in the benign ovarian cyst fluid samples is below the cutoff range. (B) Normalized Hp level in the malignant samples is above the cutoff 
range. Cutoff range is represented by a horizontal line across the plot. (C) Averaged ROC curve (red) for LR model estimated from testing data set by repeating the cross-
validation 1,000 times. The mean and sD for the aUC are estimated to be 0.966±0.03. A diagonal line is plotted to represent an ROC curve for a nondiscriminatory test.
Abbreviations: AUC, area under the curve; Hp, haptoglobin; LR, logistic regression; ROC, receiver operating characteristic.
Table 2 Diagnostic performance of SERS: sensitivity, specificity, 
PPV, and NPV of cyst fluid Hp determined by rapid SERS assay 




Test Ca non-Ca Total
Positive 51 5 56
negative 3 52 55
Total 54 57 111
95% CI
Lower Upper
sensitivity 94.40% 83.60% 98.60%
Specificity 91.20% 80% 96.70%
PPV 91.10% 79.60% 96.70%
NPV 94.50% 83.90% 98.60%
Abbreviations: CA, cancer; NPV, negative predictive value; PPV, positive 
predictive value; SERS, surface-enhanced Raman spectroscopy.
Table 3 sensitivity of rapid seRs assay for different stages of 







Notes: “n” corresponds to correct diagnosis by seRs assay. “n” corresponds to 
total number of samples in each stage.
Abbreviation: SERS, surface-enhanced Raman spectroscopy.






SERS-based assay for detection of Hp in OCFs as a diag-
nostic biomarker of EOCs is suggested in this study as an 
intraoperative diagnostic test that can inform the clinician if 
the tumor is benign or malignant in under 10 minutes, and 
facilitates decision-making during the course of laparoscopy 
or laparotomy on the immediate course of action for the 
benefit of the patient. Every year, a large number of women 
undergo laparoscopic surgery for the removal of ovarian cysts 
which are initially thought to be benign. However, a small per-
centage (<2%) of unexpected malignancy has been encoun-
tered during postsurgery tumor analysis.18–20 The choice of 
management becomes straightforward for the surgeon in 
the case of postmenopausal women. However, the choice of 
management becomes complicated in the case of nulliparous 
premenopausal women who often require a fertility-sparing 
surgery. In order to make the most appropriate decision in 
case of such an unexpected malignancy suspected during the 
course of surgery, SERS-based Hp diagnostic test will make 
an immense difference.
Ovarian cancer is mostly asymptomatic at early stages 
and possesses vague nonspecific symptoms in later stages. 
Preoperatively, the diagnosis of ovarian cancer heavily relies 
on the Risk of Malignancy Index (RMI), which is based 
exclusively on CA125 test, ultrasonography, and menopausal 
status. This method works well for advanced ovarian cancer 
and postmenopausal women. However, early stage ovarian 
cancer detection suffers because CA125 is elevated in other 
benign conditions such as endometriosis and fibrosis.21,22 
Also, in the Asian population, 50% of patients with ovarian 
cancer are premenopausal unlike the Caucasian population 
where 80% of ovarian cancer patients are postmenopausal, 
therefore affecting the RMI calculation severely.17 In this 
study, CA125 test demonstrated a sensitivity of 85% only 
and an NPV of 87%, thus leaving the false negatives for this 
method at 13%. This would also put the patients at a higher 
risk of inaccurate RMI determination.
To be intraoperatively useful in clinics, a diagnostic 
test must result in sensitive and, at the same time, fast 
detection of the biomarker. While conventional histo-
logical examination of the tumor samples can provide 
the actual stage of cancer and is used as a gold standard 
till date, the processing time of 1–2 weeks is markedly 
long. Intraoperative FS analysis has been proposed as an 
alternative as it is less time consuming and has shown 
specificity and sensitivity in clinical settings.9–11 However, 
given the logistics involved in the lengthy processing of 
the tissue, and the rate of misdiagnosed malignancy and 
Table 4 Comparison of histology results with those of diagnostic performance of SERS for different grades of cancer
Sample ID Stage Grade Histology SERS result SERS diagnosis
18 1 3 Serous carcinoma 1.09 TP
75 3 2 Serous adenocarcinoma 0.85 Fn
81 1 3 Serous carcinoma 2.10 TP
117 3 3 or 4 Serous adenocarcinoma high grade 2.25 TP
119 2 3 Serous adenocarcinoma 1.56 TP
120 1 3 High-grade serous carcinoma 1.73 TP
125 1 3 Serous adenocarcinoma 4.43 TP
126 2 3 Serous adenocarcinoma 1.49 TP
Abbreviations: Fn, false negative; SERS, surface-enhanced Raman spectroscopy; TP, true positive.
Table 5 Diagnostic performance of Ca125 vs histology: 




Test Ca non-Ca Total
Positive 46 6 52
negative 8 51 59
Total 54 57 111
 95% CI
Lower Upper
sensitivity 85.2% 72.3% 92.9%
Specificity 89.5% 77.8% 95.6%
PPV 88.5% 75.9% 95.2%
NPV 86.4% 74.5% 93.6%
Abbreviations: CA, cancer; NPV, negative predictive value; PPV, positive 
predictive value; SERS, surface-enhanced Raman spectroscopy.
Table 6 Comparison of histology results with those of CA125 







Notes: “n” corresponds to correct diagnosis by Ca125 test. “n” corresponds to 
total number of samples in each stage.
Abbreviation: SERS, surface-enhanced Raman spectroscopy.





understaged tumors,11,12 this method is still under evalu-
ation. In our study, there seemed to be 100% agreement 
of FS results with histology. However, this is not the case 
all the time. While FS analyses have been associated with 
almost 100% sensitivity in diagnosing benign tumors, the 
sensitivity reduces to 88% for malignant tumors, resulting 
in misdiagnosis of the tumors23 and suggesting that lead 
time of Hp-based SERS assay is as good as FS for intra-
operative diagnosis and may serve as a better alternative 
in clinics with no FS facility. This study, at the moment, is 
limited only to OCFs from benign and malignant tumors. 
Borderline tumors were excluded from the study in order 
to gain better understanding of the behavior of Hp in OCFs 
of benign and malignant tumors. In future, the study will 
be extended to borderline tumors. Based on the retrospec-
tive study results, we understand that the assay works best 
for benign and malignant samples in general and high-
grade tumors in particular. However, the limited number 
of samples for stage 2 and 4 can bias the sensitivity and 
specificity of the assay. Additionally, we acknowledge the 
limitations of small sample size and higher prevalence of 
malignant cases in our study, which can bias the diagnostic 
accuracies of the SERS assay. However, moving forward, 
larger clinical validation studies are required to assess the 
potential utility of this assay in clinical settings.
Conclusion
In conclusion, we report the usefulness of SERS-based 
Hp diagnostic test in differentiating benign and malignant 
tumors based on the retrospective analysis of archived OCFs 
from patients who underwent laparotomy or laparoscopy. 
Our results suggest that SERS-based assay has a high sen-
sitivity and specificity for picking up malignancy in under 
10 minutes and, more importantly, showed consistency 
across all stages of cancer. The SERS assay technology 
that is currently being developed and tested along with a 
portable read-out system holds immense promise for the 
future as a point-of-care kit to distinguish between benign 
and malignant ovarian cysts in the operation theaters during 
an ovarian cystectomy.
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Rapid surface-enhanced Raman spectroscopy (SERS) assay 
was done using 3,3′,5,5′-tetramethylbenzidine (TMB) per-
oxidase reactant, which is Raman inactive, once the comple-
tion of the peroxidase reaction in presence of (hemoglobin 
[Hb]–haptoglobin [Hp]) complex TMB2+ is formed, which 
is a Raman active product, as shown in Figure S1. Figure S2 
shows the SERS spectra of TMB2+ with the specific peaks at 
1,191, 1,337, and 1,605 cm−1, which corresponds to charac-
teristic SERS bands of TMB2+.1 With increasing concentration 
of (Hb–Hp) complex, the SERS signal intensity from TMB2+ 
also increased and there was a linear correlation between the 
SERS signal intensity and Hp concentration from 50 nm to 
34 µM, as shown in Figure S3.
Receiver operating characteristic (ROC) curve for 
CA125 present in blood serum
For the cross-validation procedure for the reliability of 
CA125 serum to predict malignant ovarian cysts, logistic 
regression was applied to construct ROC curves, which plot 
















Figure S1 Comparison of the SERS spectra for both reactant TMB and product 
TMB2+.



















Figure S2 seRs spectra with characteristic Raman bands of TMB2+.
Abbreviations: SERS, surface-enhanced Raman spectroscopy; TMB, 3,3′,5,5′- 
tetramethylbenzidine.
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Figure S3 hp concentration-dependent change in seRs intensity of TMB2+ at 1,605 
cm−1 wavenumber.
Abbreviations: Hp, haptoglobin; SERS, surface-enhanced Raman spectroscopy; 
TMB, 3,3′,5,5′-tetramethylbenzidine.
mean and SD of area under the curve (AUC) were computed 
from these ROCs.
As shown in Figure S4, averaged ROC curve (red) show-
ing the relationship between sensitivity and specificity for 
CA125 serum in the prediction of epithelial ovarian cancer, 
with the mean and SD for the AUC are estimated to be (AUC 
0.940, 95% CI 0.895–0.985; P>0.05) in N=111 cases (57 
benign cases and 54 malignant cases). A diagonal line is plot-
ted to represent an ROC curve for a nondiscriminatory test.
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Figure S4 Averaged ROC curve showing the relationship between sensitivity and 
specificity for CA125 serum in the prediction of epithelial ovarian cancer, with the 
mean and sD for the aUC estimated to be 0.940±0.023. a diagonal line is plotted to 
represent an ROC curve for a nondiscriminatory test.
Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic.
